HIGHLIGHTS
- who: Bekker et_al et al. from the University of Florida, United States have published the research work: A Randomized Controlled Dose-Escalation Study of LY06006, a Recombinant Humanized Monoclonal Antibody to RANKL, in Chinese Healthy Adults, in the Journal: (JOURNAL) of 13/05/2019
- what: This phase 1 study was conducted to explore the safety, tolerance, pharmacokinetics, pharmacodynamics and immunogenicity of LY06006 when administrated subcutaneously in healthy adults. This study provided the first-in-human data sets of LY06006. In this study, the safety, tolerability, PK, and PD of single subcutaneous administration of LY06006 were . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.